STOCK TITAN

Rapid Micro Biosystems expects going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Rapid Micro Biosystems, Inc. (RPID) expects to file its Form 10-Q for the quarter ended September 30, 2026, by November 23, 2026, under the five-calendar-day extension after saying it could not meet the required deadline without unreasonable effort or expense. The delay follows time spent evaluating financing opportunities and strategic transactions, and disclosure updates required after the company entered a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. Due to limited liquidity, the company says the 10-Q will state that substantial doubt exists about its ability to continue as a going concern one year from issuance; it says there is no assurance the acquisition will be consummated.

RPID expects preliminary total revenue of $9.5 million, up 21.6% from $7.8 million a year earlier; gross margin of $2.4 million versus $0.7 million; and operating expenses of $13.0 million versus $12.1 million. These estimates may change upon completion of the reporting process and review of the financial statements, and actual results may vary.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Preliminary quarterly revenue expected to rise 21.6% to $9.5 million.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Limited liquidity: substantial doubt about going concern one year from 10-Q issuance.
Total revenue $9.5 million Preliminary estimate for the quarter ended September 30, 2026.
Total revenue $7.8 million Quarter ended September 30, 2025; comparison stated for the preliminary estimate.
Revenue change 21.6% increase Preliminary total revenue estimate compared with the quarter ended September 30, 2025.
Gross margin $2.4 million Preliminary estimate for the quarter ended September 30, 2026.
Gross margin $0.7 million Quarter ended September 30, 2025; comparison stated for the preliminary estimate.
Operating expenses $13.0 million Preliminary estimate for the quarter ended September 30, 2026.
Operating expenses $12.1 million Quarter ended September 30, 2025; comparison stated for the preliminary estimate.
going concern financial
"ability to continue as a going concern one year from issuance"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Rule 12b-25 regulatory
"extension period provided under Rule 12b-25"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
gross margin financial
"expects to report gross margin of $2.4 million"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
preliminary estimate financial
"reflect a preliminary estimate and anticipated change"
definitive agreement technical
"entered into a definitive agreement to be acquired"
A definitive agreement is a formal, legally binding document that outlines the final terms and conditions of a deal or transaction, such as a sale or partnership. It acts like a detailed contract that confirms all parties have agreed on the key details, making the deal official. For investors, it signals that the agreement is settled and moving toward completion, providing clarity and security about the transaction.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are RPID’s preliminary results for the quarter ended September 30, 2026?

RPID expects total revenue of $9.5 million, up 21.6% from $7.8 million a year earlier; gross margin of $2.4 million versus $0.7 million; and operating expenses of $13.0 million versus $12.1 million. These estimates may change after the reporting process and financial statement review.

Why is RPID’s quarterly report late?

The company said time spent evaluating potential financing opportunities and strategic transactions diverted resources normally used to prepare the quarterly report. It also said the agreement for Merck KGaA to acquire the company requires significant disclosure updates to the report.

When does RPID expect to file its delayed quarterly report?

RPID expects to be in a position to file by November 23, 2026, the prescribed due date under the five-calendar-day extension provided by Rule 12b-25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING


(Check one):☐Form 10-K☐Form 20-F☐Form 11-K
☒Form 10-Q☐Form 10-D☐Form N-CEN☐Form N-CSR

For the Period Ended: September 30, 2026
oTransition Report on Form 10-K
oTransition Report on Form 20-F
oTransition Report on Form 11-K
oTransition Report on Form 10-Q
For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


PART I - REGISTRANT INFORMATION

RAPID MICRO BIOSYSTEMS, INC.
(Full Name of Registrant)

(Former Name if Applicable)

25 Hartwell Avenue
(Address of Principal Executive Office (Street and Number))

Lexington, MA 02421
(City, State and Zip Code)




PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒(a)The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
(b)The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c)The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Rapid Micro Biosystems, Inc. (the “Company”), is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) by the required deadline without unreasonable effort and expense. Recently, the Company has been devoting a significant amount of time and other Company resources to the evaluation of (i) potential financing opportunities to provide additional capital and improve our liquidity and (ii) potential strategic transactions. These resources would normally be devoted to the preparation of the Form 10-Q and related matters. Furthermore, earlier today, the Company announced that it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. This transaction will require significant disclosure updates to the Form 10-Q.

The Company expects to be in a position to file the Form 10-Q on or before November 23, 2026, the prescribed due date under the five calendar day extension period provided under Rule 12b-25 under the Securities Exchange Act of 1934 (the "Exchange Act").

As a result of the Company’s limited liquidity, the Form 10-Q will indicate that there is substantial doubt about the Company’s ability to continue as a going concern one year from the issuance date of the Form 10-Q, as there can be no assurance that its acquisition by Merck KGaA, Darmstadt, Germany will be consummated.

PART IV -- OTHER INFORMATION




(1)Name and telephone number of person to contact in regard to this notification
Sean Wirtjes978349-3200
(Name)(Area Code)(Telephone Number)
(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
The Company expects to report $9.5 million of total revenue for the quarter ended September 30, 2026, an increase of 21.6% from $7.8 million for the quarter ended September 30, 2025.
The Company expects to report gross margin of $2.4 million for the quarter ended September 30, 2026, compared to $0.7 million for the quarter ended September 30, 2025.
The Company expects to report $13.0 million of operating expenses for the quarter ended September 30, 2026, compared to $12.1 million for the quarter ended September 30, 2025.
The financial results presented above for the quarter ended September 30, 2026 reflect a preliminary estimate and anticipated change for the corresponding prior period as of the date of the filing of the Form 12b-25. This estimate is subject to change upon the completion of the reporting process and review of the Company’s financial statements, and actual results may vary from this estimate.
For further discussion of the significant changes in the Company’s results of operations from the corresponding period for the corresponding prior period, please refer to the Company’s earnings release furnished as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 16, 2026.

Cautionary Note Regarding Forward-Looking Statements

This Form 12b-25 includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, including statements regarding the estimated timing of the filing of the Form 10-Q, expectations regarding the Company’s ability to continue as a going concern, statements regarding the Company’s preliminary financial results for the quarter ended September 30, 2026; statements regarding the transaction with Merck KGaA, Darmstadt, Germany and any other statements regarding the Company’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors that might cause the actual performance of the Company to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the completion and filing of the Form 10-Q will take longer than expected and will not be completed by the extension period provided by Rule 12b-25 of the Exchange Act; and other risks discussed under the “Risk Factors” section in the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. These forward-looking statements speak only as of the date hereof, and the Company assumes no obligation to update any such forward-looking statements.




Rapid Micro Biosystems, Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: November 16, 2026By:/s/ Sean Wirtjes
Sean Wirtjes
Chief Financial Officer

Keep reading